Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

P. Sharman, Jeff; Coutré, Steven; R. Furman, Richard; D. Cheson, Bruce; M. Pagel, John; Hillmen, Peter; C. Barrientos, Jacqueline; D. Zelenetz, Andrew; J. Kipps, Thomas; W. Flinn, Ian; Ghia, Paolo; Eradat, Herbert; J. Ervin, Thomas; Lamanna, Nicole; Coiffier, Bertrand; R. Pettitt, Andrew; Ma, Shuo; Tausch, Eugen; Cramer, Paula; Huang, Julie; Mitra, Siddhartha; Hallek, Michael; O’Brien, Susan; Stilgenbauer, Stephan

doi:10.1200/jco.18.01460

Public

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

Published in Journal of Clinical Oncology • Apr 17, 2019

Authors:

Jeff P. Sharman

Steven Coutré

Richard R. Furman

Abstract

PURPOSE: A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm cou...

Subject

Medicine

Idelalisib

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!